West Pharmaceutical Services, Inc.

WST Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

382.92 0.10 −0.03%
Market cap
$27.0B
P/E
48.7×
Fwd P/E
37.3×
Dividend yield
0.23%
F-score
8/9
Altman Z
13.89
Beneish M
−2.79
Dividend safety
100/100

West Pharmaceutical Services, Inc. (WST) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, West Pharmaceutical Services, Inc. (WST) trades at a EV/FCF of 62.1×. Over the past ten years it has ranged from 34.6× (February 2026) to 138× (January 2017); the current reading is higher than 55% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 41.5× (52.12%)
FY2024 86.7× 41.69%
FY2023 61.2× 59.08%
FY2022 38.5× (63.40%)
FY2021 105× 50.31%
FY2020 69.9× 53.30%
FY2019 45.6× 16.59%
FY2018 39.1× (30.37%)
FY2017 56.2× (57.41%)
FY2016 132× 141.32%

Quarterly newest first

Period EV/FCF Change
Jun 2026 58.1× 48.98%
Mar 2026 39.0× (5.96%)
Dec 2025 41.5× (15.87%)
Sep 2025 49.3× 8.34%
42 more quarters

Against its own ten years

Low 34.6× High 138×
Ten-year median 60.8×
Current reading's percentile 53

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on WST